Afatinib versus Tarceva as 2nd line treatment for Squamous Cell Lung Cancer.
Patients must have had at least 4 cycles of platinum based chemotherapy and have a platelet count greater than 75,000. Platelet count must be greater than 75,000 and peripheral neuropathy is allowed if grade 2 or less.
Exclusions include, but are not limited to: Active brain metastases, Hepatitis B, C or HIV, Radiation within the last 4 weeks or malabsortion Gastrointestinal conditions.
Clinical Trial # BI 1200.45:
Afatinib for locally advanced or metastatic EGFR positive, Non Small Cell Lung Cancer. Patients are allowed to have received multiple prior treatments.
Patients must have an ECOG performance score of 0-2 and are currently unable to particpate in any other trials.
Exclusions include, but are not limited to: Left ventrical ejection fraction of less than 50, uncontrolled hypertension, poorly controlled gastrointestional disease, meningeal carcinomatosis, symptomatic brain metastasis or active Hepatitis B or C or HIV.
Clinical Trial # SPI-1014-BEL:
Carbo/taxol with Belinostat IV for Chemotherapy Naive patients diagnosed with stage IV Non Small Cell Lung Cancer( Adenocarcinoma or Squamous Cell) .
Participants must be stage IV with a hemoglobin of 9.0 or higher.
Exclusions include, but are not limited to: Prior cancer within 5 years, Grade 2 neuropathy or higher, HIV, Hepatitis B, Hepatitis C, Unstable systemic steroid doses or active infection within the past 2 weeks.